Aortoiliac Occlusive Disease
- Author: Kenneth E McIntyre Jr, MD; Chief Editor: Vincent Lopez Rowe, MD more...
Background
In patients with peripheral arterial disease, obstructing plaques caused by atherosclerotic occlusive disease commonly occur in the infrarenal aorta and iliac arteries. Atherosclerotic plaques may induce symptoms either by obstructing blood flow or by breaking apart and embolizing atherosclerotic and/or thrombotic debris to more distal blood vessels. If the plaques are large enough to impinge on the arterial lumen, reduction of blood flow to the extremities occurs. Several risk factors exist for development of the arterial lesions, and recognition of these factors enables physicians to prescribe nonoperative treatment that may alleviate symptoms as well as prolong life.
Surgical treatment of aortoiliac occlusive disease (AIOD) has been well standardized for many years, and the outcomes are quite good. However, the additional techniques of percutaneous transluminal angioplasty (PTA) and stenting have offered more alternatives to open surgery and offer successful techniques to patients who may have been considered at an unacceptably high risk for conventional open surgical repairs. Catheter-based endovascular treatments for aortoiliac occlusive disease (AIOD) offer the advantages of less morbidity, faster recovery, and shorter hospital stays. In fact, most endovascular interventions today are simply performed as outpatient procedures. This chapter reviews the risk factors for development of atherosclerotic occlusive disease of the aorta and iliac arteries and describes the natural history, diagnosis, and treatment of the disease.
An image depicting atherosclerosis can be seen below.
Type I atherosclerosis with occlusive disease limited to the infrarenal aorta and common iliac arteries. For excellent patient education resources, visit eMedicine's Cholesterol Center. Also, see eMedicine's patient education articles High Cholesterol and Cholesterol FAQs.
History of the Procedure
Before prosthetic grafts for aortic bypasses became available, the first direct surgical reconstructions on the aorta were performed using the technique of thromboendarterectomy (TEA), first described by Dos Santos of Lisbon in 1947.[1] The initial procedure was performed on a patient with superficial femoral artery (SFA) obstruction, and Dos Santos termed the procedure disobliteration. Edwin J. Wylie, MD, adapted this technique to the aortoiliac region and, in 1951, performed the first aortoiliac endarterectomy in the United States.[2] With the discovery of suitable prosthetic graft materials for aortic replacement in the 1960s, surgical treatment of aortoiliac occlusive disease (AIOD) became available to even more patients.
In 1964, Dotter first performed percutaneous iliac angioplasty using a coaxial system of metal dilators.[3] This procedure proved to have limited application due to the cumbersome nature of the device. However, Dotter's early work paved the way for Grüntzig, who, in 1974, developed a catheter with an inflatable polyvinyl chloride balloon that could be passed over a guidewire.[4] This device became the cornerstone for the percutaneous treatment of arterial occlusive lesions today. In 1985, Julio Palmaz introduced the first stent that helped to improve the results of angioplasty for arterial occlusive disease.[5] Since the advent of angioplasty and stenting, the technology has evolved at an astronomical rate. The design and quality of endovascular devices, as well as the ease and accuracy of performing the procedures, have improved. These improvements have led to improved patient outcomes following endovascular interventions for aortoiliac occlusive disease (AIOD).
Problem
Aortoiliac occlusive disease (AIOD) occurs commonly in patients with peripheral arterial disease (PAD). Significant lesions in the aortoiliac arterial segment are exposed easily by palpation of the femoral pulses. Any diminution of the palpable femoral pulse indicates that a more proximal obstruction exists. Obstructive lesions may be present in the infrarenal aorta, common iliac, internal iliac (hypogastric), external iliac, or combinations of any or all of these vessels. Occasionally, degenerated nonstenotic atheromatous disease exists in these vessels and may manifest by atheroembolism to the foot, the "blue toe" or "trash foot" syndrome.
Aboyans et al found that patients with aortoiliac peripheral arterial disease (PAD) have a poorer general prognosis than those with more distal PAD. Their review of 400 patients with PAD showed that after adjustment for age, sex, cardiovascular disease history and risk factors, critical leg ischemia status, and treatments, proximal PAD was significantly associated with a worse prognosis (hazard ratio [HR] for death, nonfatal myocardial infarction or stroke, and coronary or carotid revascularization: 3.28; HR for death ratio: 3.18, p < 0.002 vs. distal PAD).[6]
Epidemiology
Frequency
At least half of patients with peripheral arterial disease (PAD) have no symptoms, and, therefore, the exact incidence and prevalence of the condition is unknown. However, the incidence of PAD is known to increase with advancing age so that, by age 70 years, as many as 25% of the US population is affected. Occlusive disease involving the aortoiliac arterial segment occurs commonly in patients with peripheral arterial disease (PAD) and is second only to occlusive disease of the SFA in frequency.
Etiology
Atherosclerosis is the most common etiology of occlusive plaques in the aorta and iliac arteries. Several risk factors exist for the development of atherosclerotic plaques in the aortoiliac arterial segment. Cigarette smoking and hypercholesterolemia are observed more commonly in patients with aortoiliac occlusive disease (AIOD) as compared with infrainguinal occlusive disease. In addition, patients with aortoiliac occlusive disease (AIOD) tend to be younger and less likely to have diabetes.
An uncommon cause of aortic obstruction is Takayasu disease, a nonspecific arteritis that may cause obstruction of the abdominal aorta and its branches. The etiology of Takayasu disease is not known. For the purpose of this chapter, only occlusive lesions caused by atherosclerosis are considered.
Pathophysiology
Atherosclerosis is an extraordinarily complex degenerative disease with no known single cause. However, many variables are known to contribute to the development of atherosclerotic lesions. One popular theory emphasizes that atherosclerosis occurs as a response to arterial injury. Factors that are known to be injurious to the arterial wall include mechanical factors such as hypertension and low wall shear stress, as well as chemical factors such as nicotine, hyperlipidemia, hyperglycemia, and homocysteine.
Lipid accumulation begins in the smooth muscle cells and macrophages that occur as an inflammatory response to endothelial injury, and the "fatty streak" begins to form in the arterial wall. The atheroma consists of differing compositions of cholesterol, cholesterol esters, and triglycerides. Some plaques are unstable, and fissures occur on the surface of the plaque that expose the circulating platelets to the inner elements of the atheroma. Platelet aggregation then is stimulated. Platelets bind to fibrin through activation of the glycoprotein (Gp) IIb/IIIa receptor on the platelets, and a fresh blood clot forms in the area of plaque breakdown. These unstable plaques are prone to atheromatous embolization and/or propagation of clot that eventually can occlude the arterial lumen.
If the atheroma enlarges enough to occupy at least 50% of the arterial lumen, the flow velocity of blood through that stenosis can significantly increase. The oxygen requirements of the lower extremity at rest are low enough that even with a moderate proximal stenosis, no increase in blood flow velocity occurs. During exercise, however, the oxygen debt that occurs in ischemic muscle cannot be relieved because of the proximal obstruction of blood flow; this results in claudication symptoms. In more advanced cases, critical tissue ischemia occurs, and neuropathic rest pain or tissue loss ensues. However, critical limb ischemia is seldom, if ever, caused by aortoiliac occlusive disease (AIOD) alone. Commonly, in patients with critical limb ischemia, multiple arterial segments are involved in the occlusive atherosclerotic process.
Presentation
The most common symptom of patients with hemodynamically significant aortoiliac disease is claudication. The word claudication stems from the Latin word claudicatio, to limp. The symptom complex of claudication is defined as muscle cramps in the leg(s) that occur following exercise and are relieved by resting. In any individual patient, the exercise distance at which claudication occurs is quite constant. Claudication usually occurs first in the calf muscles, although thigh, hip, and buttocks muscles also can be affected when more extensive proximal lesions are present. Location of the muscle pain (ie, calf vs thigh) does not necessarily correlate with the level of arterial obstruction. However, more proximal symptoms (ie, buttocks or thigh claudication) are generally associated with severe aortoiliac occlusive disease.
Symptoms of buttock claudication can occur in association with erectile dysfunction in patients with absent femoral pulses. This constellation of symptoms is termed Leriche syndrome, named for the surgeon who described the condition in 1923. Leriche syndrome occurs when either preocclusive stenosis or complete occlusion of the infrarenal aorta is present due to severe aortic atherosclerosis. Due to the chronic nature of the occlusive process leading to development of rich collateral vessels that supply the lower extremity, limb-threatening ischemia seldom occurs.
Indications
Treatment of patients with peripheral arterial disease (PAD) has 2 goals. The first and foremost goal is to reduce the risk of vascular events (myocardial infarction, stroke, vascular death) that occur at an alarmingly high rate in patients with PAD. About 30% of patients with peripheral arterial disease (PAD) die within 5 years, and death is usually due to an ischemic coronary event.
The second goal of treatment is to improve symptoms in those patients with claudication and prevent amputation in patients with critical limb ischemia. Critical limb ischemia is present when patients have symptoms of ischemic rest pain, nonhealing foot ulcers, or gangrene, and its presence mandates urgent evaluation with aortography and endovascular and/or surgical revascularization to prevent limb loss.
At least half of patients with peripheral arterial disease (PAD) are asymptomatic and are diagnosed only by physical examination and/or measurement of the ankle/brachial index (ABI). An ABI less than 0.9 clearly is abnormal and confirms the diagnosis of peripheral arterial disease (PAD). An abnormal ABI should alert the clinician to the fact that this group of patients is at risk for early mortality from cardiovascular causes, ie, myocardial infarction, stroke, other vascular death. The goal for treatment of asymptomatic patients is to reduce the risk of subsequent vascular events.
Relevant Anatomy
Three distinct arterial segments distal to the visceral bearing portion of the abdominal aorta may become diseased by atherosclerosis. Type I atherosclerosis involves the infrarenal aorta and common iliac arteries only. This pattern of atherosclerosis is present in about 5-10% of patients with peripheral arterial disease (PAD) and occurs more commonly in women. The vessels distal to the common iliac arteries usually are generally normal or only minimally diseased. Type II atherosclerosis involves the infrarenal aorta, common and external iliac arteries, and may extend into the common femoral arteries. This pattern is observed in 35% of patients with peripheral arterial disease (PAD). Type III atherosclerosis is the most severe form and, unfortunately, also the most common. This pattern of atherosclerosis involves the infrarenal aorta, iliac, femoral, popliteal, and tibial arteries.
Diabetes mellitus is a risk factor that results in a characteristic pattern of atherosclerotic lesions in patients with peripheral arterial disease (PAD). The proximal inflow (aorta, iliac) arteries tend be normal. However, the femoropopliteal segment (including the profunda femoris artery), and especially the proximal tibial arteries, are usually severely diseased. Fortunately, the distal tibial and plantar vessels may be normal, enabling successful arterial reconstruction for limb-threatening ischemia.
Contraindications
At least 50% of patients with peripheral arterial disease (PAD) may be asymptomatic. Because natural history data are poor for iliac stenosis, surgical and/or endovascular intervention should not be considered if patients truly are asymptomatic. Surgical intervention for limb-threatening ischemia is accepted universally, unless the limb is deemed nonviable. Determining whether or not to intervene in a patient with mild claudication may not be as straightforward.
An important role exists for conservative therapy in patients with aortoiliac occlusive disease (AIOD). Although surgical therapy usually alleviates symptoms, the patient must be apprised of the operative risk of mortality (2-3%) as well as anticipated outcomes over time. Since the advent of catheter-based treatments for aortoiliac occlusive disease (AIOD), asymptomatic patients are often treated prophylactically with either angioplasty or stenting of iliac arterial lesions that are discovered during coronary angiography. This practice of drive-by angioplasty should not be recommended.
Dos Santos JC. Sur la desobstruction des thrombus arterielles anciennes. Mem Acad Chir. 1947;73:409.
Wylie EJ. Thromboendarterectomy for arteriosclerotic thrombosis of major arteries. Surgery. 1952;23:275-292.
Dotter C, Judkins M. Transluminal treatment of arteriosclerotic obstruction: Description of a new technique and a preliminary report of its application. Circulation. Nov 1964;30:654-70. [Medline].
Grüntzig A, Hopff H. [Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique) (author's transl)]. Dtsch Med Wochenschr. Dec 6 1974;99(49):2502-10, 2511. [Medline].
Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. Radiology. Jul 1985;156(1):73-7. [Medline].
[Best Evidence] Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. Mar 2 2010;55(9):898-903. [Medline].
Weitz JI, Byrne J, Clagett GP. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. Dec 1 1996;94(11):3026-49. [Medline].
Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. Sep 27 1995;274(12):975-80. [Medline].
Blaisdell FW, Hall AD. Axillary femoral bypass for lower extremity ischemia. Surgery. 1963;54:563.
Ichihashi S, Higashiura W, Itoh H, Sakaguchi S, Nishimine K, Kichikawa K. Long-term outcomes for systematic primary stent placement in complex iliac artery occlusive disease classified according to Trans-Atlantic Inter-Society Consensus (TASC)-II. J Vasc Surg. Apr 2011;53(4):992-9. [Medline].
Chang IS, Park KB, Do YS, et al. Heavily Calcified Occlusive Lesions of the Iliac Artery: Long-Term Patency and CT Findings After Stent Placement. J Vasc Interv Radiol. Aug 2011;22(8):1131-1137.e1. [Medline].
Baker JD. Physiologic studies to document severity of aortoiliac occlusive disease. In: Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St. Louis, Mo: Mosby-Year Book, Inc; 2001.
Ballard JL, Bergan JJ, Singh P, et al. Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost. J Vasc Surg. Jul 1998;28(1):94-101; discussion 101-3. [Medline].
Ballard JL, Sparks SR, Taylor FC, et al. Complications of iliac artery stent deployment. J Vasc Surg. Oct 1996;24(4):545-53; discussion 553-5. [Medline].
Barbera L, Mumme A, Metin S, et al. Operative results and outcome of twenty-four totally laparoscopic vascular procedures for aortoiliac occlusive disease. J Vasc Surg. Jul 1998;28(1):136-42. [Medline].
Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. Jul 1997;204(1):87-96. [Medline].
Brewster DC. Current controversies in the management of aortoiliac occlusive disease. J Vasc Surg. Feb 1997;25(2):365-79. [Medline].
Brewster DC, Darling RC. Optimal methods of aortoiliac reconstruction. Surgery. Dec 1978;84(6):739-48. [Medline].
Cambria RP, Brewster DC, Abbott WM, et al. Transperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. J Vasc Surg. Feb 1990;11(2):314-24; discussion 324-5. [Medline].
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. Jan 8 1994;308(6921):81-106. [Medline].
Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. Mar 1985;71(3):510-5. [Medline].
Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. Feb 6 1992;326(6):381-6. [Medline].
DeBakey ME, Cooley DA, Crawford ES. Clinical application of a new flexible knitted Dacron arterial substitute. Am J Surg. 1958;24:862.
Donaldson MC, Louras JC, Bucknam CA. Axillofemoral bypass: a tool with a limited role. J Vasc Surg. May 1986;3(5):757-63. [Medline].
el-Massry S, Saad E, Sauvage LR, et al. Axillofemoral bypass with externally supported, knitted Dacron grafts: a follow-up through twelve years. J Vasc Surg. Jan 1993;17(1):107-14; discussion 114-5. [Medline].
Ernst E, Fialka V. A review of the clinical effectiveness of exercise therapy for intermittent claudication. Arch Intern Med. Oct 25 1993;153(20):2357-60. [Medline].
Funovics MA, Lackner B, Cejna M, et al. Predictors of long-term results after treatment of iliac artery obliteration by transluminal angioplasty and stent deployment. Cardiovasc Intervent Radiol. Sep-Oct 2002;25(5):397-402.
Harrington ME, Harrington EB, Haimov M, et al. Iliofemoral versus femorofemoral bypass: the case for an individualized approach. J Vasc Surg. Dec 1992;16(6):841-52; discussion 852-4. [Medline].
Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. Mar 1 1995;91(5):1472-9. [Medline].
Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. Jan 2001;119(1 Suppl):283S-299S. [Medline].
Legemate DA, Teeuwen C, Hoeneveld H, et al. Value of duplex scanning compared with angiography and pressure measurement in the assessment of aortoiliac arterial lesions. Br J Surg. Aug 1991;78(8):1003-8. [Medline].
Malone JM, Moore WS, Goldstone J. The natural history of bilateral aortofemoral bypass grafts for ischemia of the lower extremities. Arch Surg. Nov 1975;110(11):1300-6. [Medline].
McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. Apr 1991;87(2-3):119-28. [Medline].
Messina LM. Endarterectomy for atherosclerotic aortoiliac occlusive disease. In: Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St. Louis, Mo: Mosby-Year Book, Inc; 2001:381-4.
Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. Sep 1993;88(3):837-45. [Medline].
Passman MA, Taylor LM, Moneta GL, et al. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. Feb 1996;23(2):263-9; discussion 269-71. [Medline].
Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio. Circulation. Jan 1994;89(1):511-31. [Medline].
Prendiville EJ, Burke PE, Colgan MP, et al. The profunda femoris: a durable outflow vessel in aortofemoral surgery. J Vasc Surg. Jul 1992;16(1):23-9. [Medline].
Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. Jan 1996;23(1):104-15. [Medline].
Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. Feb 20 1986;314(8):488-500. [Medline].
Said S, Mall J, Peter F, Muller JM. Laparoscopic aortofemoral bypass grafting: human cadaveric and initial clinical experiences. J Vasc Surg. Apr 1999;29(4):639-48. [Medline].
Schafer AL. Antiplatelet therapy. Am J Med. Aug 1996;101(2):199-209. [Medline].
Schneider PA. Endovascular or open surgery for aortoiliac occlusive disease?. Cardiovasc Surg. Aug 2002;10(4):378-82. [Medline].
Sharp WJ, Hoballah JJ, Mohan CR, et al. The management of the infected aortic prosthesis: a current decade of experience. J Vasc Surg. May 1994;19(5):844-50. [Medline].
Stoney RJ, Reilly LM. Endarterectomy for aortoiliac occlusive disease. In: Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. St. Louis, Mo: Mosby-Year Book, Inc; 1987:157.
Szilagyi DE, Elliott JP, Smith RF. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg. Mar 1986;3(3):421-36. [Medline].
Szilagyi DE, Smith RF, Elliott JP, et al. Infection in arterial reconstruction with synthetic grafts. Ann Surg. Sep 1972;176(3):321-33. [Medline].
TASC Working Group. Endovascular procedures for intermittent claudication. J Vasc Surg. 2000;31:S97-S112.
Taylor Jr LM, Moneta GL, Porter JM. Natural history and non-operative treatment of chronic lower extremity ischemia. Vasc Surg. 2000;928-43.
Yeager RA, Moneta GL, Taylor LM, et al. Improving survival and limb salvage in patients with aortic graft infection. Am J Surg. May 1990;159(5):466-9. [Medline].

